Free Trial
NASDAQ:CAPS

Capstone Therapeutics (CAPS) Stock Price, News & Analysis

Capstone Therapeutics logo
$1.22 0.00 (0.00%)
As of 04:00 PM Eastern

About Capstone Therapeutics Stock (NASDAQ:CAPS)

Key Stats

Today's Range
$1.21
$1.30
50-Day Range
$1.01
$1.80
52-Week Range
$0.96
$16.18
Volume
213,517 shs
Average Volume
1.22 million shs
Market Capitalization
$6.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CAPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CAPS Stock News Headlines

Michael Parker
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
A capstone project
Capstone Holding Corp. (J7W.F)
See More Headlines

CAPS Stock Analysis - Frequently Asked Questions

Capstone Therapeutics' stock was trading at $2.40 at the beginning of the year. Since then, CAPS shares have decreased by 48.3% and is now trading at $1.2399.

Capstone Therapeutics Corp. (NASDAQ:CAPS) posted its earnings results on Friday, August, 15th. The company reported ($0.13) earnings per share for the quarter. The business earned $12.85 million during the quarter.

Capstone Therapeutics (CAPS) raised $5 million in an IPO on Thursday, March 6th 2025. The company issued 1,250,000 shares at a price of $4.00 per share.

Capstone Therapeutics's lock-up period expires on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its initial public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/15/2025
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CAPS
CIK
887151
Web
N/A
Employees
38
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
0.97
Quick Ratio
0.41

Sales & Book Value

Annual Sales
$44.88 million
Price / Sales
0.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
5,580,000
Free Float
3,192,000
Market Cap
$6.81 million
Optionable
N/A
Beta
-0.80
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CAPS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners